[EN] PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE JANUS
申请人:MERCK SHARP & DOHME
公开号:WO2013085802A1
公开(公告)日:2013-06-13
The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.
Disclosed are substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
公开了作为HIF脯氨酰羟化酶抑制剂的有用取代嘧啶,用于治疗贫血及类似病症。
[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYCLOALKYLNITRILE PYRAZOLOPYRIDONES UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146490A1
公开(公告)日:2014-09-25
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
[EN] ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE<br/>[FR] ÉTHERS D'ARYLPYRAZOLE EN TANT QU'INHIBITEURS DE LEUCOTRIÈNE A4 HYDROLASE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2013012844A1
公开(公告)日:2013-01-24
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
[EN] PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA<br/>[FR] INHIBITEURS PURIQUES DE LA PHOSPHATIDYLINOSITOL 3-KINASE DELTA HUMAINE
申请人:MERCK SHARP & DOHME
公开号:WO2014075393A1
公开(公告)日:2014-05-22
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.